Black Diamond Therapeutics, Inc. Common Stock (BDTX)
Black Diamond Therapeutics, Inc. (BDTX) is a biotechnology company focused on developing precision oncology medicines. It utilizes its unique oncology master key platform to identify and target specific genetic mutations in cancer, aiming to deliver personalized treatment options for patients with difficult-to-treat tumors.
Company News
Black Diamond Therapeutics reported a narrower net loss in Q2 2025, with improved operational efficiency and focus on silevertinib clinical development. The company completed Phase 2 trial enrollment and maintains a cash runway through Q4 2027.
Servier and Black Diamond Therapeutics have announced a global licensing agreement for BDTX-4933, a targeted oncology therapy in Phase 1 development. Servier will lead the development and commercialization of the therapy, with Black Diamond receiving an upfront payment and potential milestone and royalty payments.
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Stay informed with the latest financial news and updates.
The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider tr...